BIBW-2992. Dual EGFR/HER2 inhibitor oncolytic

Drugs of the Future

Volumn 33, Issue 8, 2008, Pages 649-654

  Campas C ^a   Castaner R ^a   Bolos J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 CHLORO 4 (2 PYRIDINYLMETHOXY)ANILINO] 3 CYANO 6 (4 DIMETHYLAMINOCROTONAMIDO) 7 ETHOXYQUINOLINE; ANGIOGENESIS INHIBITOR; BIBF 1120; BIBW 2992; CANERTINIB; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; GEFITINIB; LAPATINIB; N [4 (3 CHLORO 4 FLUOROPHENYLAMINO) 7 (TETRAHYDROFURAN 3 YLOXY)QUINAZOLIN 6 YL] 4 (DIMETHYLAMINO) 2 BUTENAMIDE; PACLITAXEL; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TOVOK; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

ACNE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER INHIBITION; CANCER RESISTANCE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DYSPNEA; GASTROINTESTINAL SYMPTOM; HALF LIFE TIME; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NONHUMAN; PROSTATE CANCER; PROSTATE CARCINOMA; PRURITUS; RECOMMENDED DRUG DOSE; SINGLE DRUG DOSE; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TUMOR REGRESSION;

EID: 59349102970     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.08.1237313     Document Type: Article

References (36)

1. Himmelsbach, F., Langkopf, E., Solca, F., Jung, B., Baum, A., Blech, S. (Boehringer Ingelheim Pharma GmbH & Co., KG). Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof. DE 10063435, EP 1345910, JP 2004516283, US 2002173509, US 2006100223, US 7019012, WO 0250043.
2. Soyka, R., Rall, W., Kulinna, C., Sieger, P., Schnaubelt, J. (Boehringer Ingelheim Pharma GmbH & Co., KG). Process for preparing amino crotonyl compounds. DE 10349113, EP 1678165, JP 2007510624, US 2005085495, WO 2005037824.
3. Reid, A., Vidal, L., Shaw, H., de Bono, J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer 2007, 43(3): 481-9.
4. Baselga, J., Arteaga, C. L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005, 23(11): 2445-59.
5. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., McGuire, W.L. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785): 177-82.
6. Britten, C.D. Targeting ErbB receptor signalling: A pan-ErbB approach to cancer. Mol Cancer Ther 2004, 3(10): 1335-42.
7. Riely, G.J. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Thorac Oncol 2008, 3(6, Suppl. 2): S146-9.
8. Xia, W., Lau, Y.-K., Zhang, H.-Z. et al. Combination of EGFR, HER-2/ neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 1999, 5(12): 4164-74.
9. Solca, F., Baum, A., Guth, B., Colbatzky, F., Blech, S., Amelsberg, A., Himmelsbach, F. BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor for cancer therapy. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst A244.
10. Yang, C., Shih, J., Chao, T. et al. Use of BIBW 2992, a novel irreversible EGFR/HER2 TKI, to induce regression in patients with adenocarcinoma of the lung and activating EGFR mutations: Preliminary results of a single-arm phase II clinical trial. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(20, Suppl.): Abst 8026.
11. Solca, F., Schweifer, N., Baum, A., Rudolph, D., Amelsberg, A., Himmelsbach, F., Beug, H. BIBW 2992, an irreversible dual EGFR/HER2 kinase inhibitor, shows activity on L858R/T790M EGFR mutants. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst A242.
12. Bean, J., Riely, G.J., Balak, M., Marks, J.L., Ladanyi, M., Miller, V.A., Pao, W. Acquired resistance to epidermal growth factor receptor (EGFR) kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(20, Suppl.): Abst 8056.
13. Shimamura, T., Greulich, H., Solca, F.F., Wong, K.-K. Efficacy of BIBW-2992, a potent irreversible inhibitor of EGFR and HER2 in human NSCLC xenografts in a transgenic mouse lung-cancer model. J Thorac Oncol [12th World Conf Lung Cancer (Sept 2-6, Seoul) 2007] 2007, 2(8, Suppl. 4): Abst C7-04.
14. Solca, F., Baum, A., Krause, M., Baumann, M., Wong, K.K., Greulich, H., Adolf, G. Efficacy of BIBW 2992, a potent irreversible inhibitor of EGFR and HER2, in models of head and neck cancer. Eur J Cancer Suppl 2007, 54(4): Abst 5508.
15. Schütze, C., Dörfler, A., Eicheler, W. et al. Combination of EGFR/HER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma. Strahlenther Onkol 2007, 183(5): 256-64.
16. Solca, F., Baum, A., Himmelsbach, F., Amelsberg, A., Adolf, G. Efficacy of BIBW 2992, an irreversible dual EGFR/HER2 inhibitor, in combination with cytotoxic agents. Eur J Cancer - Suppl 2006, 4(12): Abst 567.
17. Stopfer, P., Narjes, H., Gaschler-Markefski, B., Gansser, D., Shahidi, M. Pharmacokinetics (PK) of [14C]-BIBW 2992 after administration of a single dose of 15 mg [14C]-BIBW 2992 oral solution in healthy male volunteers. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008) 2008, 26(20, Suppl,): Abst 14607.
18. Stopfer, P., Schaefer, H.G., Amelsberg, A. et al. Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-16, Philadelphia) 2005, Abst B172.
19. Mom, C.H., Eskens, F.A., Gietema, K. et al. Phase 1 study with BOW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006] 2006, 24(18, Suppl.): Abst 3025.
20. Eskens, F.A., Mom, C.H., Planting, A.S. et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer 2008, 98(1): 80-5.
21. Lewis, N., Marshall, J., Amelsberg, A., Cohen, R.B., Stopfer, P., Hwang J., Malik, S. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours, 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 3091.
22. Marshall, J., Lewis, N.L., Amelsberg, A., Briscoe, J., Hwang, J., Malik, S., Cohen, R. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumours. 17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther (Nov 14-18, Philadelphia) 2005, Abst B161.
23. Agus, D.B., Terlizzi, E., Stopfer, P., Amelsberg, A., Gordon, M.S. A phase 1 dose escalation study of BIBW 2992, an irreversible dual EGFR/ HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. 42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006, Abst 2074.
24. Shaw, H., Plummer, R., Vidal, L. et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours. J Clin Oncol [42nd Annu Meet Am Soc Clin Oncol (ASCO) (June 3-6, Atlanta) 2006) 2006, 24(18, Suppl.): Abst 3027.
25. Plummer, R., Vidal, L., Perrett, R. et al. A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/ HER2 inhibitor. Eur J Cancer - Suppl 2007, 5(4): Abst 703.
26. Spicer, J., Calvert, H., Vidal, L. et al. Activity of BIBW2992, an oral irreversible dual EGFR/HER2 inhibitor, in non-small cell lung cancer (NSCLC) with mutated EGFR. J Thorac Oncol 2007, 2(8, Suppl. 4): Abst D7-02.
27. Bouché, O., Ducreux, M., Lledo, G. et al. A phase II trial of weekly alternating sequential administration of BIBF1120 and BIBW2992 in patients with advanced colorectal cancer. J Clin Oncol [44th Annu Meet Am Soc Clin Oncol (ASCO) (May 30-June 3, Chicago) 2008] 2008, 26(20, Suppl.): Abst 15001.
28. An open label phase II trial of BIBW 2992 in patients with HER2-negative metastatic breast cancer (NCT00425854). Clinical Trials.gov Web site, July 28, 2008.
29. Phase II trial of BIBW 2992 in patients with HER2-positive metastatic breast cancer after failure of trastuzumab therapy (NCT00431067). ClinicalTrials.gov Web site, July 28, 2008.
30. BIBW 2992 and letrozole in hormonoresistant metastatic breast cancer (NCT00708214). ClinicalTrials.gov Web site, July 28, 2008.
31. BIBW 2992 in head&neck cancer (NCT00514943). ClinicalTrials.gov Web site, July 28, 2008.
32. Study to determine the maximum tolerated dose of BIBW 2992 (TOVOK) when combined with cisplatin/paclitaxel or cisplatin/5-FU in patients with advanced solid tumours (NCT00716417). ClinicalTrials.gov Web site, July 28, 2008.
33. BIBF 1120 versus BIBW 2992 versus sequential administration of BIBF 1120 and BIBW 2992 in patients with hormone-resistant prostate cancer (NCT00706628). ClinicalTrials.gov Web site, July 28, 2008.
34. Phase I/II open label trial of continuous once daily oral treatment with BIBW 2992 - Phase I trial in advanced non small cell lung cancer patients & phase II trial in non small cell lung cancer patients failing erlotinib or gefitinib (NCT00711594). ClinicalTrials.gov Web site, July 28, 2008.
35. BIBW 2992 (TO VOK) and BSC versus placebo and BSC in non-small cell lung cancer patients failing erlotinib or gefitinib (NCT00656136). ClinicalTrials.gov Web site, July 28, 2008.
36. FDA grants fast track status to Boehringer Ingelheim's BIBW-2992 for NSCLC. DailyDrug News. com, February 15, 2008.